Aktuell
- pANCHO p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer (NCT00525200)
- MIOMIE prospective randomized trial for the evaluation of perioperative morbidity in patients with esophageal cancer - open versus minimally invasive esophagectomy
- GABIS Gastroesophageal Cancer Biopsy Studie - Evaluation of Tumorheterogenity of Her-2 expression in patients with gastroesophageal cancer
- SAS-1 Study - Evaluation for Radiofrequency ablation in combination with anti-reflux procedure in patients with low-grade dysplasia and non-dysplastic Barretts
- Phase II study of Oxaliplatin/ Irinotecan/ Bevacizumab followed by Docetaxel/ Bevacizumab in inoperable locally advanced or metastatic gastric cancer patients
Zukünftig
- Indikationserweiterungsstudie bei Patient:innen mit minimal metastasierten gastroösophagealen Karzinomen
- SAKK 75/08. Multimodal therapy with and without cetuximab in patients with locally advanced esophageal carcinoma. An open-label phase III trial
- Screening for human epidermal growth factor receptor 2 (HER2) positivity in patients with inoperable locally advanced or metastatic gastric or gastro-esophageal junction (GEJ) cancer
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in c-Met Enriched Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Phase II trial of the long-acting somatostatin analogue octreotide (Sandostatin LAR) combined with chemotherapy consisting of 5-FU/Cisplatin in patients with advanced gastric cancer